Amgen's MariTide injectable GLP-1 with monthly dosing offers a credible third entrant to challenge Lilly/Novo if Phase 3 data reads out clean. Repatha, Prolia, and Tezspire continue to drive base business growth. Horizon Therapeutics integration synergies are tracking ahead. Biosimilar Humira and Stelara competition provides cash flow visibility.
Signals scoped to US · Company-specific tagging coming soon.